Neurology® Podcast

1) Clinical specificities of patients with NMDA receptor antibodies encephalitis and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Jerome Honnorat about his paper on the clinical specificities of patients with NMDA receptor antibodies encephalitis. Dr. James Addington is reading our e-Pearl of the week about posterior interosseous nerve syndrome. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Apixaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Addington and Chaturvedi.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) ASA/clopidogrel combination confers better long term vascular protection in ASA failure and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Robert Cote about his paper on whether the combination of ASA/clopidogrel confers better long term vascular protection in ASA failure. Dr. James Addington is reading our e-Pearl of the week about hypoglycorrhachia. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Dabigatran), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Cote, Addington, Southerland and Chaturvedi.Dr. Cote served on the scientific advisory board for Bayer Schering Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer Inc; serves on the scientific advisory board for DSMB for National Institute of Health (Point Study), Steering committee for the National Institute of Health (SPS3 study); is a consultant for Otsuka Pharmaceutical Co., Ltd.; received speaker honoraria from Boehringer Ingelheim, Merck Serono, Sanofi-aventis.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

Interviews with Bill Seely on frontotemporal dementia. Clinical presentations & bedside evaluation, diagnostic testing & genetics, therapeutics & future directions.

1) High dose midazolam infusion for refractory status epilepticus and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Jan Claassen about his paper on high dose midazolam infusion for refractory status epilepticus. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in early onset epileptic encephalopathies. In the next part of the podcast Dr. Matt Barrett interviews Dr. Vicki Shanker about clinical approach to non-Parkinson disease tremor. The participants had nothing to disclose except Drs. Claassen and Numis. Dr. Claassen serves as an editorial board member of Neurocritical Care.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Drs. Riley Bove and Philip De Jager about their paper on the influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women. Dr. Adam Numis is reading our e-Pearl of the week about parechovirus and neurologic disease. In the next part of the podcast Dr. Binit Shah interviews Dr. Anthony Lang about non-neurodegenerative causes of parkinsonism - drug-induced; structural: NPH, stroke, tumor; psychogenic. The participants had nothing to disclose except Drs. Burns, Bove, De Jager, Numis and Lang.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Bove receives research support from Partners Healthcare, National Multiple Sclerosis Society and the NIH.Dr. De Jager serves as an editorial board member of the Journal of Neuroimmunology; serves on the scientific advisory board for Teva Neuroscience, Genzyme/Sanofi; receives speakers' honoraria from Biogen Idec and Source Healthcare Analytics, LLC; receives research support from Biogen Idec, GlaxoSmithKline, Genzyme/Sanofi, Vertex Pharmaceuticals and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lang served as an advisor for Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Inc, Merck Serono, Novartis, NeuroPhage Pharmaceuticals, Teva Pharmaceutical Industries Ltd, UCB.; received research support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; served as an expert witness in cases related to the welding industry.

1) Guideline on assessment and management of psychiatric disorders in individuals with multiple sclerosis and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Sarah Minden about AAN paper on assessment and management of psychiatric disorders in individuals with multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about airplane headache. In the next part of the podcast Dr. Binit Shah interviews Dr. Melissa Armstrong about diagnosis, management and prognosis of atypical parkinsonian disorders. The participants had nothing to disclose except Drs. Keegan, Minden, Numis and Armstrong.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Minden received honoraria and travel reimbursement for meetings from Pfizer Inc, Merck Serono, Genentech, Inc., Novartis, and Avanir Pharmaceuticals; received research support from the National Multiple Sclerosis Society, the Center for Mental Health Services, and the Substance Abuse and Mental Health Services Administration; holds stock options in Merck Serono, Schering-Plough Corp, and GlaxoSmithKline.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Armstrong serves on the Level of Evidence Review Team for Neurology®; is an evidence-based guideline methodology consultant for the AAN; receives research support from Abbvie as local sub-investigator; received a 2011 Movement Disorders Society travel Scholarship to the MDS International Congress; and in 2010-2011 was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.

The New MS Drugs

1) Effect of head impacts on diffusivity measures in collegiate contact sport athletes and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Noah Kolb interviews Dr. Thomas McAllister about his paper on effect of head impacts on diffusivity measures in collegiate contact sport athletes. Dr. Adam Numis is reading our e-Pearl of the week about recurrent rhabdomyolysis. In the next part of the podcast Dr. Matt Barrett interviews Dr. Dan Weintraub about management of neuropsychiatric manifestations of Parkinson disease. The participants had nothing to disclose except Drs. McAllister, Numis and Weintraub.Dr. McAllister receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal; serves on the scientific advisory board of Pfizer Inc, Teva Pharmaceutical Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Eli Lilly and Company, Biogen Idec, Lundbeck Inc., UCB, Bristol-Myers Squibb, CHDI Foundation, Inc, ADCS; receives fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson disease; receives commercial funding for travel from Teva Pharmaceutical Industries Ltd.; gave expert testimony for defense in 2012-2013 in lawsuit related to impulse control disorders in Parkinson disease; receives research support from Novartis, Michael J. Fox Foundation for Parkinson's Research and the NIH.

1) Building foundations for improving health opportunities in sub-Saharan Africa and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Wong interviews Dr. Michael Finkel about his paper on building foundations for improving health opportunities in sub-Saharan Africa. Dr. Roy Strowd is reading our e-Pearl of the week about neurapraxia. In the next part of the podcast Dr. Michelle Mauermann interviews Dr. Kerry Levin on part two of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Finkel, Strowd and Levin.Dr. Finkel gave expert testimony as a treating physician in 2012.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Levin serves as an editorial board member of Muscle and Nerve; serves on the scientific advisory board of the American Board of Psychiatry and Neurology; received reimbursement for travel to policy meetings and examination writing committees from the American Board of Psychiatry and Neurology; receives royalties from UpToDate.